JAK/STAT Signaling

Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.

Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.

EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively.

EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer.

JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor

Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity

BI-1622 is an orally effective and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. BI-1622 has a selectivity for EGFR greater than 25-fold. In transplant mouse models of H2170 and PC9 cells, BI-1622 showed high in vivo anti-tumor effects and has good activity molecular metabolism and pharmacokinetic properties.

BI-4142 is an effective, highly selective, orally active HER2 inhibitor with an IC50 value of 5 nM.

Butyzamide is an orally effective Mpl activator, where Mpl is a receptor for thrombopoietin (TPO) involved in platelet production. Butyzamide increases the phosphorylation levels of JAK2, STAT3, STAT5 and MAPK. In mouse xenograft experiments, Butyzamide increases human platelet levels.

Disitamab (RC48-0) is a humanized monoclonal antibody that targets HER2. Disitamab can be used to synthesize antibody-drug conjugates (ADCs), such as Disitamab vedotin.

Dosimertinib-d5 (mesylate) is an effective orally active EGFR inhibitor. It reduces the expression of p-EGFR and p-ERK proteins. Dosimertinib-d5 (mesylate) exhibits anti-proliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has potential for research in non-small cell lung cancer (NSCLC).

EGFR-IN-70 (compound 18j) is an effective EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFRLR/TM/CS and EGFRWT, respectively. It has anti-proliferative activity and inhibits the phosphorylation of EGFR. EGFR-IN-70 can be used in cancer research.